SHL Receives Good Design Award for Molly Auto Injector
SHL Molly auto injector receives Good Design Award for its innovative design and related business model.
Deerfield Beach, FL, October 05, 2011 --(PR.com)-- SHL Group is honored to have recently received certification for the Good Design Award for its revolutionary auto injector, Molly. This prestigious award, with more than 50 years of history, has dedicated itself to recognizing outstanding designs that can further advance lifestyle and industrial activity, both of which are embraced by Molly’s innovative design and related business model.
Officially introduced to biopharmaceutical customers in late 2010, Molly was designed to offer not only a number of enhanced device features to benefit patients, but also establish an alternative business model that makes more sense for customers and allows them to get their product to market even faster. Some key design features of Molly include compact size, permanently hidden needle, locking needle shield, and a simple 2-step operation with integrated safety features. The concept of patients using an auto injector to self-administer injections safely in the comfort of their own home is a significant contribution to advancing patient lifestyles and also their quality of life (QOL). The unique design features that the Molly device utilize help to further enhance patient compliance by focusing on convenience, safety and offering a device that end users are comfortable with using.
Although the commercial applications of the Molly auto injector will depend on the corresponding biopharmaceutical customer, it is likely to be intended for therapeutic areas that require frequent injections either at home or in a clinical environment, leading to high volume demands. Auto injectors are becoming more commonly used to deliver medications that treat a variety of therapeutic areas such as RA, Oncology, Diabetes, MS and many others. As a result, mass production will be required to support the demand for this device and in turn stimulate various industrial activities to support the manufacturing processes required for development.
The achievements of Molly, SHL’s first pre-configured auto injector, have raised the bar for similar devices and SHL will continue to invest in project and design teams to bring to the industry new innovations that will benefit patients throughout the world.
About SHL
SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 1,600 staff globally (over 1000 staff in Taiwan), with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia.
SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Our organization consists of three distinct group companies:
SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
For additional information visit www.shl-group.com or contact us at
SHL Media Contact
Steven R. Kaufman
Marketing Director
###
Officially introduced to biopharmaceutical customers in late 2010, Molly was designed to offer not only a number of enhanced device features to benefit patients, but also establish an alternative business model that makes more sense for customers and allows them to get their product to market even faster. Some key design features of Molly include compact size, permanently hidden needle, locking needle shield, and a simple 2-step operation with integrated safety features. The concept of patients using an auto injector to self-administer injections safely in the comfort of their own home is a significant contribution to advancing patient lifestyles and also their quality of life (QOL). The unique design features that the Molly device utilize help to further enhance patient compliance by focusing on convenience, safety and offering a device that end users are comfortable with using.
Although the commercial applications of the Molly auto injector will depend on the corresponding biopharmaceutical customer, it is likely to be intended for therapeutic areas that require frequent injections either at home or in a clinical environment, leading to high volume demands. Auto injectors are becoming more commonly used to deliver medications that treat a variety of therapeutic areas such as RA, Oncology, Diabetes, MS and many others. As a result, mass production will be required to support the demand for this device and in turn stimulate various industrial activities to support the manufacturing processes required for development.
The achievements of Molly, SHL’s first pre-configured auto injector, have raised the bar for similar devices and SHL will continue to invest in project and design teams to bring to the industry new innovations that will benefit patients throughout the world.
About SHL
SHL is the world’s largest privately-owned designer, developer and manufacturer of advanced drug delivery devices. We have over 1,600 staff globally (over 1000 staff in Taiwan), with our primary design centers located in the USA and Sweden and manufacturing centers located in Asia.
SHL supplies auto injectors, pen injectors and inhaler systems to global pharmaceutical and biotech companies. Significant investment in R&D has enhanced our broad pipeline of “next generation” drug delivery systems. These innovative devices include a range of disposable and reusable injectors with fixed or variable dosing, enhanced precision and the ability to accommodate high viscosities.
Our organization consists of three distinct group companies:
SHL Medical
Designs, develops and manufactures advanced drug delivery devices for leading pharmaceutical and biotech companies
SHL Healthcare
Develops and manufactures equipment solutions for home, hospital and long term care use
SHL Technologies
Provides contract manufacturing and engineering services for the production of complex medtech and industrial products
For additional information visit www.shl-group.com or contact us at
SHL Media Contact
Steven R. Kaufman
Marketing Director
###
Contact
SHL Group (Scandinavian Health Group Ltd)
Steven Kaufman
+886-3-2170303
www.shl-group.com
Steven Kaufman
+886-3-2170303
www.shl-group.com
Contact
Categories